In the Claims

Please replace previous versions of the claims with the following:

1.-22. (Cancelled)

23. (Currently Amended) A pharmaceutical composition comprising:

a pharmaceutically acceptable agent ~~agents~~; and

a compound selected from one of Formula I and Formula II, and pharmaceutically acceptable salts thereof:



Formula I



Formula II

where Formulae I and II include all possible geometric, racemic, diasteriomeric, and enantiomeric forms and where:

R^1 is selected from H, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl-$(C_1\text{-}C_6)$alkenyl, aryl and azaaromatic;

R^2 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkene, and $(C_2\text{-}C_6)$alkynyl, and in Formula I, R^2 may additionally be selected from O= or HN=;

R^3 is selected from hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, and aryl$(C_1\text{-}C_6)$alkyl; and

R^4 is $(C_1\text{-}C_6)$alkyl, and $(C_3\text{-}C_6)$cycloalkyl; and R^5 is aryl or azaaromatic and may form a bond to R^1 to result in a conjugated ring system; ~~and~~

~~wherein said~~ in an amount [[is]] sufficient to induce ~~anlgesia~~ analgesia and/or deter abuse of abusive substances.

24. (Previously Presented) The composition of claim 23, wherein R^1 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, aryl$(C_1\text{-}C_6)$alkyl, N-methylamino, N,N-dimethylamino, carboxylate, $(C_1\text{-}C_3)$alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

25. (Previously Presented) The composition of claim 23, wherein R^5 is selected from the group consisting of aryl and azaaromatic, each having 1-5 substituents independently selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, $(C_2\text{-}C_6)$alkenyl, aryl, aryl$(C_1\text{-}C_6)$alkyl, N-methylamino, N,N-dimethylamino, carboxylate, $(C_1\text{-}C_3)$alkylcarboxylate, carboxaldehyde, acetoxy, propionyloxy, isopropionyloxy, cyano, aminomethyl, N-methylaminomethyl, N,N-dimethylaminomethyl, carboxamide, N-methylcarboxamide, N,N-dimethylcarboxamide, acetyl, propionyl, formyl, benzoyl, sulfate, methylsulfate, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, thiol, methylthio, ethylthio, propiothiol, fluoro, chloro, bromo, iodo, trifluoromethyl, propargyl, nitro, carbamoyl, ureido, azido, isocyanate, thioisocyanate, hydroxylamino, and nitroso.

26. (Previously Presented) The composition of claim 23 wherein R^3 is methyl or ethyl.

27. (Cancelled)

28. (Previously Presented) The pharmaceutical composition according to claim 23, wherein said analogs are in the form of pharmaceutically acceptable salts.

29. (Previously Presented) The pharmaceutical composition of claim 28, wherein said pharmaceutically acceptable salts are inorganic acid addition salts, organic acid addition salts, salts with acidic amino acids, and hydrates or solvates thereof with alcohols and other solvents.

30. (Previously Presented) The pharmaceutical composition of claim 29, wherein said analog is an inorganic acid addition salt selected from the group consisting of hydrochloride, hydrobromide, sulfate, phosphate and nitrate.

31. (New) The pharmaceutical composition of claim 23, wherein the composition blocks an nAChR.

32. (New) The pharmaceutical composition of claim 31, wherein the nAChR is the $\alpha 3\beta 4$ receptor.